Drug Trial Radar · NCT02467270
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
283
Actual
Start
Jul 13, 2015
Primary completion
Apr 29, 2020
Study completion Apr 23, 2025
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.
Conditions
- Myeloid Leukemia, Chronic, Chronic Phase
Interventions
PonatinibDrug
Tablet, taken orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12Time frame: 12 months after the first dose of study treatment
Locations
86 sites in 21 countries. Site status is shown where the registry gives one.
Emory University Winship Cancer Institute
Atlanta, Georgia
Indiana Blood & Marrow Transplantation
Indianapolis, Indiana
University of Maryland Medical Center
Baltimore, Maryland
Michigan Medicine
Ann Arbor, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
University of Minnesota Medical School
Minneapolis, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center - New York
New York, New York
NewYork-Presbyterian Weill Cornell Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Cleveland Clinic Taussig Cancer Institute Main Campus
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Abramson Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah
Fundaleu
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital General de Agudo Jose Maria Ramos Mejia
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Italiano La Plata
La Plata, Buenos Aires, Argentina
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Princess Margaret Hospital - Toronto
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Saskatchewan Cancer Agency
Regina, Saskatchewan, Canada
Hospital del Salvador
Providencia, Santiago Metropolitan, Chile
Centro de Investigaciones Clinicas Vina del Mar
Viña del Mar, Valparaiso, Chile
Fakultni Nemocnice Olomouc
Olomouc, Czechia
Ustav Hematologie a Krevni Transfuze Praha
Prague, Prague, Czechia
Aarhus University Hospital
Aarhus C, \Aarhus, Denmark
Centre de Lutte Contre le Cancer - Institut Bergonie
Bordeaux, Aquitaine, France
Centre Hospitalier Regional Universitaire de Lille
Lille, Hauts-de-France, France
Centre Hospitalier Universitaire de Nancy Hopital de Brabois
Vandœuvre-lès-Nancy, Lorraine, France
Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, Midi-pyrenees, France
Center Hospitalier Universitaire d'Angers
Angers, Pays de la Loire Region, France
Centre Hospitalier Universitaire de Nantes Hotel Dieu
Nantes, Pays de la Loire Region, France
Centre Hospitalier Universitaire de Poitiers
Poitiers, Poitou-charentes, France
Centre Hospitalier Universitaire de Nice Hopital l'Archet
Nice, Provence-Alpes-Côte d'Azur Region, France
Charite Universitatsmedizin Berlin
Berlin, Germany
Universitatsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitaetsklinikum Heidelberg
Mannheim, Baden-Wurttemberg, Germany
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.